You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 143 No. 12, December 2007 TABLE OF CONTENTS
  Archives
  •  Online Features
  Research Letters
 This Article
 •PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal
 Topic Collections
 •Dermatologic Disorders
 •Dermatologic Disorders, Other
 •Drug Therapy
 •Adverse Effects
 •Alert me on articles by topic
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

High Procalcitonin Levels in Patients With Severe Drug Reactions

Mehdi Sfia, MD; Peggy Boeckler, MD; Dan Lipsker, MD, PhD

Arch Dermatol. 2007;143(12):1591.

Although procalcitonin (PCT) serum level is still considered to be a highly specific and sensitive biologic marker of severe bacterial infections, it can be increased in noninfectious situations such as diffuse metastatic solid cancers,1 C-cell carcinoma of the thyroid gland,2 major trauma or surgery,3-4 or after cardiopulmonary bypass.5 Herein we show that PCT level increases in some patients with severe drug reactions. Clinicians should therefore not rely on PCT values to discriminate between infectious and immunoallergic eruptions in patients who present with fever and a rash.

Methods

We investigated 8 consecutive patients with a severe cutaneous drug eruption. Four patients had Stevens-Johnson syndrome (SJS); 2 had drug rash, eosinophilia, and systemic symptoms syndrome (DRESS); 1 had acute generalized exanthematous pustulosis; and 1 had Lyell syndrome. The diagnosis of drug eruption was based on clinical, biologic, and histologic findings. In all cases, investigations including routine biology tests, blood cultures, urinary bacterial examination, pulmonary radiography, and serology failed to identify any bacterial or viral agent.


Results

Procalcitonin levels were significantly elevated in 2 patients, one with DRESS (3.96 µg/L) and the other with SJS (0.53 µg/L). All patients healed within a mean of 25 days (range, 15-45 days) without any antibiotic treatment.


Comment

Our findings suggest that in some patients with severe drug eruptions, PCT level can be elevated in the absence of bacterial infection. Thus, elevated PCT levels neither predict infection in patients with severe drug rashes nor allow discrimination between infectious and noninfectious eruptions.


AUTHOR INFORMATION

Correspondence: Dr Lipsker, Clinique Dermatologique, Hopitaux Universitaites, 1 Place de l’Hopital, 67091 Strasbourg CEDEX, France (dan.lipsker{at}gmail.com).

Financial Disclosure: None reported.


REFERENCES

1. Matzaraki V, Alexandraki KI, Venetsanou K; et al. Evaluation of serum procalcitonin and interleukin-6 levels as markers of liver metastasis. Clin Biochem. 2007;40(5-6):336-342. FULL TEXT | ISI | PUBMED
2. Bertagna XY, Nicholson WE, Pettengill OS, Sorenson GD, Mount CD, Orth DN. Ectopic production of high molecular weight calcitonin and corticotropin by human small cell carcinoma cells in tissue culture: evidence for separate precursors. J Clin Endocrinol Metab. 1978;47(6):1390-1393. FREE FULL TEXT
3. Meisner M, Tschaikowsky K, Hutzler A, Schick C, Schuttler J. Postoperative plasma concentrations of procalcitonin after different types of surgery. Intensive Care Med. 1998;24(7):680-684. FULL TEXT | ISI | PUBMED
4. Mimoz O, Benoist JF, Edouard AR, Assicot M, Bohuon C, Samii K. Procalcitonin and C-reactive protein during the early posttraumatic systemic inflammatory response syndrome. Intensive Care Med. 1998;24(2):185-188. FULL TEXT | ISI | PUBMED
5. Meisner M, Tschaikowsky K, Schmidt J, Schüttler J. Procalcitonin (PCT)—indications for a new diagnostic parameter of severe bacterial infection and sepsis in transplantation, immunosuppression, and cardiac assist devices. Cardiovasc Eng. 1996;1(1):67-76.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 2007 American Medical Association. All Rights Reserved.